Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients

Inclusion Criteria: * Histologically confirmed newly diagnosed intermediate to high grade soft tissue sarcoma localized to the extremities, trunk and chest wall or the head and neck area, for which the standard treatment is a combination of and radiotherapy and surgery(deep seated and/or \> 5cm according to the RECIST 1.1 criteria and/or an anticipated close resection margin and/or grade II/III according to the WHO definition) * Age ≥ 18 years * WHO performance status of ≤ 1 * Able and willing to undergo blood sampling for PK and PD analysis * Able to swallow and retain oral medication * Able and willing to undergo MRI scanning * Able and willing to undergo tumor biopsies * Adequate organ functions as described by the laboratory findings in the table 1. For thyroid function, the T4 and TSH values must be within normal values of the range of the participating centers * Written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up. Exclusion Criteria * Prior malignancies; except another malignancy and disease-free for ≥ 5 years, or completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma. * Patients with recurrent sarcomas (even without prior radiotherapy) * Ewing sarcoma and other PNET family tumors, rhabdomyosarcomas (both pediatric and adult), osteosarcomas * Clinically significant gastrointestinal abnormalities which might interfere with oral dosing…